Souders Financial Advisors Lowers Stock Holdings in Amgen Inc. $AMGN

Souders Financial Advisors decreased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.4% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,643 shares of the medical research company’s stock after selling 520 shares during the period. Souders Financial Advisors’ holdings in Amgen were worth $1,575,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Cetera Trust Company N.A raised its position in Amgen by 0.7% during the second quarter. Cetera Trust Company N.A now owns 9,353 shares of the medical research company’s stock valued at $2,611,000 after purchasing an additional 65 shares in the last quarter. Achmea Investment Management B.V. increased its holdings in shares of Amgen by 34.1% in the second quarter. Achmea Investment Management B.V. now owns 201,714 shares of the medical research company’s stock worth $56,320,000 after buying an additional 51,293 shares during the period. HORAN Wealth LLC purchased a new position in shares of Amgen in the second quarter worth about $3,831,000. SouthState Corp increased its holdings in shares of Amgen by 3.8% in the second quarter. SouthState Corp now owns 25,177 shares of the medical research company’s stock worth $7,030,000 after buying an additional 920 shares during the period. Finally, Sienna Gestion increased its holdings in shares of Amgen by 10.7% in the second quarter. Sienna Gestion now owns 22,311 shares of the medical research company’s stock worth $5,687,000 after buying an additional 2,148 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on AMGN. Weiss Ratings upgraded Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Citigroup lifted their price objective on Amgen from $310.00 to $315.00 and gave the stock a “neutral” rating in a report on Wednesday, September 24th. Wells Fargo & Company lifted their price objective on Amgen from $280.00 to $300.00 and gave the stock an “overweight” rating in a report on Wednesday. Piper Sandler reiterated an “overweight” rating on shares of Amgen in a report on Wednesday. Finally, Bank of America lifted their price objective on Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a report on Friday, September 26th. Eight research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $307.33.

Amgen Stock Performance

Amgen stock opened at $319.86 on Thursday. The stock’s 50 day simple moving average is $288.69 and its two-hundred day simple moving average is $287.99. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The stock has a market cap of $172.20 billion, a price-to-earnings ratio of 26.15, a PEG ratio of 2.61 and a beta of 0.45. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $335.88.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. The business had revenue of $9.56 billion for the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business’s revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 12th. Shareholders of record on Friday, November 21st will be given a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.0%. The ex-dividend date of this dividend is Friday, November 21st. Amgen’s payout ratio is presently 73.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.